Biomea Fusion, Inc.

Biomea Fusion, Inc.

BMEA·NASDAQ

$1.38

+6.2%
HealthcareBiotechnology

Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.

At a Glance

Live Snapshot
Market Cap$82.10M
EPS-1.1800
P/E Ratio-1.17
Earnings Date08/03/2026

No Dividend Yield Data

BMEA has not reported any dividend yield values in the available annual periods.

No Dividend Payout Ratio Data

BMEA has not reported any dividend payout ratio values in the available annual periods.

No Net Dividends Paid Data

BMEA has not reported any net dividends paid values in the available annual periods.

Biomea Fusion, Inc.

Biomea Fusion, Inc. Dividend History

BMEA · NASDAQ
10Y CAGR +0%
Latest $0
Annual $0
Stable dividend payments
Last Period: +0%

BMEA Dividend Payment History

BMEA · NASDAQ
DeclarationEx-DatePayment DateDividendAdjustedFrequencyGrowth
No dividend payment history available
bmea

Biomea Fusion, Inc. Payout Ratio Analysis

BMEA · NASDAQ
Dividends Paid
0.00
2025
Net Income
-61.80M
2025
Payout Ratio
0.00%
2025

Dividend Sustainability Analysis

Payout Ratio
0.00%

Conservative payout with excellent safety margin. Company retains significant earnings for growth, acquisitions, or building cash reserves. Dividend is highly sustainable.

FCF Payout Ratio
0.0%

Negative free cash flow while paying dividends is a major red flag. Company burning cash and cannot sustain dividend without external financing.

Sustainability
At Risk

Dividend appears unsustainable based on current metrics. High probability of reduction or elimination. Proceed with caution.